Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Desensitization therapy for antituberculous drugs].

Y Kobashi1, N Okimoto, T Matsushima

  • 1Department of Medicine, Kawasaki Medical School Kawasaki Hospital, Okayama, Japan.

Kekkaku : [Tuberculosis]
|November 9, 2000
PubMed
Summary

Desensitization therapy for antituberculous drugs like Rifampicin and Isoniazid is effective for patients with adverse reactions. This treatment shows a high success rate, enabling continued use of essential tuberculosis medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.

Oncogene·2016
Same author

miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells.

British journal of cancer·2015
Same author

Education and Imaging. Hepatology: Hepatocellular carcinoma with duodenal metastasis.

Journal of gastroenterology and hepatology·2015
Same author

Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction.

British journal of cancer·2013
Same author

NOTCH1 expression predicts patient prognosis in esophageal squamous cell cancer.

European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes·2013
Same author

Correlation between variable-number tandem-repeat-based genotypes and drug susceptibility in Mycobacterium avium isolates.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2011

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Medicine

Context:

  • Adverse reactions to antituberculous drugs can limit treatment options.
  • Tuberculosis treatment often relies on key drugs like Rifampicin and Isoniazid.
  • Patient management requires strategies to overcome drug intolerances.

Purpose:

  • To evaluate the effectiveness of desensitization therapy for Rifampicin (RFP) and Isoniazid (INH) in patients experiencing adverse reactions.
  • To determine the success rates of desensitization protocols for RFP and INH.
  • To identify factors influencing the success of antituberculous drug desensitization.

Summary:

  • Retrospective analysis of 28 cases (29 episodes) with adverse reactions to RFP and INH.
  • Desensitization for RFP achieved a 79% success rate (19/24 episodes).

Related Experiment Videos

  • Desensitization for INH achieved an 83% success rate (10/12 cases).
  • No significant differences were found between successful and unsuccessful desensitization regarding patient history or treatment parameters.
  • Overall success rate for desensitization to both drugs was approximately 80%.

    • Impact:

    • Desensitization therapy offers a viable option for continuing essential antituberculous treatment in patients with adverse effects.
    • High success rates suggest desensitization can improve adherence and outcomes in tuberculosis management.
    • This approach expands therapeutic possibilities for patients previously restricted from using critical TB drugs.